Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Longeveron (LGVN)
NASDAQ:LGVN
Holding LGVN?
Track your performance easily
Earnings Data
Report Date
Mar 07, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.37Last Year’s EPS
-$2.5Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -23.48%
|Next Earnings Date:Mar 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a largely positive outlook with significant milestones achieved in HLHS and Alzheimer's programs, financial growth, and a strategic focus on advancing stem cell therapies. However, challenges remain in Alzheimer's development and securing additional financing.Company Guidance
During the Longeveron (LGVN) Q3 2024 earnings call, the management provided several metrics highlighting their progress and strategic direction. The company reported a significant revenue increase of 177% to $1.8 million for the first nine months of 2024, driven by heightened demand in their frailty and cognitive impairment registry trial and new contract manufacturing revenue. They emphasized the potential of their product Lomecel-B, which has been administered to over 540 patients across five clinical trials in three indications, including Alzheimer’s disease and hypoplastic left heart syndrome (HLHS). Their Phase 2b ELPIS II trial for HLHS has achieved over 80% enrollment, with expectations to complete by early next year. Additionally, they received several FDA designations, including orphan drug and Fast Track for HLHS, and RMAT and Fast Track for Alzheimer's. Their cash reserves, totaling $22.8 million, are projected to fund operations through the fourth quarter of 2025, despite a 14% year-over-year reduction in operating expenses. The company is preparing for a rolling BLA submission in 2026, contingent on positive trial results, and continues to strategize around future clinical and regulatory pathways.Significant Milestones in Stem Cell Therapy
Longeveron marks the 10th anniversary of its founding, highlighting progress in stem cell therapy including FDA approval of stem cell-based treatments and advancements in regenerative medicine.
Positive Developments in HLHS Program
The ELPIS II study for HLHS has achieved over 80% enrollment, with the potential for a BLA submission. The ELPIS I trial shows 100% 5-year post-treatment survival with no heart transplants.
Alzheimer's Disease Program Advancements
Lomecel-B received RMAT and Fast Track designations for Alzheimer's. Positive results from the CLEAR MIND Phase 2a trial presented at major conferences.
Financial Growth and Expense Management
Revenues increased by 177% to $1.8 million for the first 9 months of 2024. Operating expenses decreased by 14% year-over-year.
---
LGVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LGVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $2.30 | $2.12 | -7.83% |
| Aug 14, 2024 | $2.61 | $2.46 | -5.75% |
| May 14, 2024 | $1.39 | $1.34 | -3.60% |
| Feb 27, 2024 | $5.79 | $5.44 | -6.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Longeveron (LGVN) report earnings?
Longeveron (LGVN) is schdueled to report earning on Mar 07, 2025, TBA Not Confirmed.
What is Longeveron (LGVN) earnings time?
Longeveron (LGVN) earnings time is at Mar 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGVN EPS forecast?
LGVN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.37.
---